Welcome to our dedicated page for Petros Pharmaceuticals SEC filings (Ticker: PTPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Petros Pharmaceuticals’ push to move its flagship erectile dysfunction therapy from prescription to over-the-counter status makes each SEC disclosure dense with FDA milestones, R&D outlays, and device-segment margins. Finding where the company details Additional Conditions for Nonprescription Use or breaks down vacuum erection system revenue inside a 300-page document can slow even seasoned analysts.
Stock Titan’s platform turns that obstacle into clarity. Our AI-powered summaries translate the legal language of every Petros Pharmaceuticals annual report 10-K simplified, pinpoint the latest Petros Pharmaceuticals quarterly earnings report 10-Q filing, and surface Petros Pharmaceuticals 8-K material events explained within minutes of hitting EDGAR. Need to follow Petros Pharmaceuticals Form 4 insider transactions real-time? We stream alerts on executive stock transactions as they occur, then overlay context so you understand whether insiders are buying ahead of pivotal FDA meetings. The same engine answers natural questions like “understanding Petros Pharmaceuticals SEC documents with AI” or “Petros Pharmaceuticals proxy statement executive compensation” directly on the page.
Whether you’re comparing clinical trial spending quarter-over-quarter, gauging market reception to a potential Rx-to-OTC switch, or monitoring Petros Pharmaceuticals insider trading Form 4 transactions for sentiment cues, every filing type is organized and annotated. You’ll get Petros Pharmaceuticals earnings report filing analysis, governance insights, and risk-factor highlights without wading through jargon. Real-time updates, comprehensive coverage, and expert commentary give you the confidence to act on what matters most.
Petros Pharmaceuticals, Inc. (PTPI) has had its common stock removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, certifying that it complied with its rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing and/or registration. The filing is signed on behalf of Nasdaq by a hearings advisor, confirming Nasdaq’s action to delist PTPI’s common stock from the exchange.
Petros Pharmaceuticals (PTPI) filed its Q3 2025 10‑Q. The company exited legacy products, recorded a $6.97 million gain from assigning subsidiaries and a Vivus settlement, and reported nine‑month net income of $2.25 million. From continuing operations, it posted a loss of $4.16 million; large preferred-related deemed dividends and warrant items drove a nine‑month loss per share of $1.95.
Liquidity remains tight: cash was $6,070,266 and working capital was $3.4 million as of September 30, 2025, with substantial doubt about continuing as a going concern. Stockholders’ equity improved to $3,368,087 from a deficit at year‑end 2024. A February 2025 financing raised $9.6 million gross (about $8.5 million net). The company effected a 1‑for‑25 reverse split on April 30, 2025, and its common stock was delisted from Nasdaq and now trades on the OTC Market.
Capital structure shifted materially: investors exercised Series B warrants via alternative cashless exercise for 39,208,828 shares during the period. Common shares outstanding were 42,284,502 at September 30, 2025, and 42,372,260 as of November 12, 2025.
Petros Pharmaceuticals (PTPI) reported a Nasdaq delisting process. Nasdaq notified the company on November 3, 2025 that it intends to announce the delisting of Petros’ common stock. Nasdaq will file a Form 25 to deregister the stock under Section 12(b), and the delisting becomes effective ten days after that filing.
The stock was suspended from The Nasdaq Capital Market on May 22, 2025 and has traded on the OTCID Basic Market under “PTPI” since July 1, 2025. Petros states trading on the OTCID will continue without disruption, and the company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.
FAQ
What is the current stock price of Petros Pharmaceuticals (PTPI)?
What is the market cap of Petros Pharmaceuticals (PTPI)?
